Biogen Acquires Human Immunology Biosciences for up to $1.8B
May 22, 2024
Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.
- Buyers
- Biogen Inc.
- Targets
- Human Immunology Biosciences
- Sellers
- Human Immunology Biosciences stockholders, ARCH Venture Partners, Monograph Capital, Alpha Wave Global, Arkin Bio Capital, Jeito Capital, Viking Global Investors
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.